Life sciences real estate proves pandemic-proof (The Asset) While the last 18 months in the Asia-Pacific region have been difficult for commercial real estate investors, especially in the office, retail and hospitality segments, due to the Covid-19 pandemic, one sector that has not experienced any significant issues in the region is that of life sciences real estate.
This has proven providential for Singapore-based Lighthouse Canton, an integrated investment firm for institutional investors and accredited private clients, which only invests in life sciences real estate and has not experienced any significant issues.
"Because life sciences or the pharmaceutical or biotechnology sectors have traditionally been a defensive industry, the industry has done well," says Shilpi Chowdhary, Lighthouse Canton's CEO in an interview with The Asset. "And with Covid-19 being a healthcare crisis, everybody, including governments, realize that they need to be investing more in healthcare and life sciences, and we expect that...
